Ashraf Z. Badros, MB, ChB, discusses the results of the phase 3 AURIGA trial which evaluated daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its potential to expand ...

Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years ...

In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...